Skip to main content

Depemokimab Cuts Exacerbation Rate in Eosinophilic Asthma

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 11, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Sept. 10, 2024 -- For patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a study published online Sept. 9 in the New England Journal of Medicine to coincide with the European Respiratory Society Congress, held from Sept. 7 to 11 in Vienna.

David J. Jackson, Ph.D., from King's College London, and colleagues examined the efficacy and safety of depemokimab in patients with severe asthma and an eosinophilic phenotype characterized by a high eosinophil count and a history of exacerbations despite receipt of medium- or high-dose inhaled glucocorticoids. Participants across two trials were randomly allocated to receive depemokimab (100 mg subcutaneously) or placebo at weeks 0 and 26, plus standard care (502 and 260, respectively).

The researchers found that the annualized rate of exacerbations was 0.46 and 1.11 with depemokimab and placebo, respectively, in SWIFT-1 and 0.56 and 1.08, respectively, in SWIFT-2 (rate ratios, 0.42 and 0.52). The change from baseline in the score on the St. George's Respiratory Questionnaire did not differ significantly between groups in either trial. Both groups had a similar proportion of patients with any adverse event.

"The administration of depemokimab every six months reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype," the authors write.

Two authors disclosed ties to GSK, which funded the study.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Antibiotic Exposure Before Age 2 May Increase Risk for Chronic Pediatric Conditions

WEDNESDAY, April 30, 2025 -- Children receiving multiple antibiotic courses between birth and age 2 years may have a higher risk for some chronic conditions, according to a study...

School-Based Asthma Therapy Boosts Asthma Control, Cuts Acute Health Care Use

THURSDAY, April 24, 2025 -- School-based asthma therapy (SBAT) can help improve children’s asthma control and decrease acute health care utilization, according to a study...

Midafternoon Dosing Improves Lung Function in Atopic Asthma

FRIDAY, April 18, 2025 -- Midafternoon dosing with beclomethasone dipropionate is associated with better clinical outcomes in mild-to-moderate atopic asthma, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.